AZD-1305

• UNSPSC Description:

  AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research[1][2].

• Target Antigen:

  Calcium Channel; Potassium Channel; Sodium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/azd-1305.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(OC(C)(C)C)NCCN1CC(O2)CN(CCOC3=CC=C(C#N)C=C3F)CC2C1

• Molecular Weight:

  434.50

• References & Citations:

  [1]Alexander Burashnikov, et al. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol. 2010 Jul;56(1):80-90. |[2]Charles Antzelevitch, et al. AZD1305 Exerts Atrial Predominant Electrophysiological Actions and Is Effective in Suppressing Atrial Fibrillation and Preventing Its Reinduction in the Dog. [J] Cardiovasc Pharmacol. 2010, Volume 56，Number 1. |[3]Serge Sicouri, et al. Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2010, Volume 334，Number 1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  872045-91-5